<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1193">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04655612</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0624</org_study_id>
    <nct_id>NCT04655612</nct_id>
  </id_info>
  <brief_title>Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases</brief_title>
  <acronym>COVID-RIC1</acronym>
  <official_title>Seroprevalence Study of CoV-2-SARS (COVID-19) Infection in Patients With Chronic Inflammatory Rheumatic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet&#xD;
      been widely reported, and has been evaluated only in symptomatic patient samples. The&#xD;
      proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share&#xD;
      common symptoms with CoV-2-SARS infection. Our objective is to describe the prevalence of&#xD;
      seroconversion to CoV-2-SARS by consecutive screening in routine care of patients with&#xD;
      chronic inflammatory rheumatism with serological testing&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prevalence of SARS-CoV-2 infection in chronic inflammatory rheumatic diseases has not yet&#xD;
      been widely reported, and has been evaluated only in symptomatic patient samples. The&#xD;
      proportion of asymptomatic or mildly symptomatic patients is unknown, in patients who share&#xD;
      common symptoms with CoV-2-SARS infection.&#xD;
&#xD;
      Some treatments for chronic inflammatory rheumatisms such as TNF inibitors appear to have a&#xD;
      protective effect against severe forms of COVID-19, while corticosteroids or other&#xD;
      immunosuppressants may be associated with a higher prevalence of severe forms of COVID-19.&#xD;
&#xD;
      Our objective is to describe the prevalence of seroconversion to CoV-2-SARS by consecutive&#xD;
      screening in routine care of out and inpatients with chronic inflammatory rheumatism (i.e.&#xD;
      rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis) by serological testing&#xD;
      and to compare prevalence according to type of chronic inflammatory rheumatism, DMARD class&#xD;
      and symptomatic treatment (corticosteroid therapy, NSAIDs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of patients with inflammatory chronic rheumatic diseases with positive SARS-CoV-2 serodiagnosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to current treatments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to type of chronic inflammatory rheumatic disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics</measure>
    <time_frame>1 day</time_frame>
    <description>Proportion of patients with a positive CoV-2 SARS serodiagnosis according to demographic characteristics</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV Infection</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Ankylosing Spondylitis</condition>
  <condition>Psoriatic Arthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive outpatients and inpatients with inflammatory chronic rheumatism disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        - Patient with chronic inflammatory rheumatic disease (i.e. rheumatoid arthritis, psoriatic&#xD;
        rheumatism, axial spondyloarthritis), Coming for consultation or hospitalization as part of&#xD;
        the usual follow-up of his condition&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Adult patient under legal protection (guardianship, curatorship)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Morel, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>UH MONTPELLIER</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thao Pham, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Morel, MD, PhD</last_name>
    <phone>+33 467 337 791</phone>
    <email>j-morel@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thao Pham, MD, PhD</last_name>
    <email>thao.pham@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre hopsitalier universitaire de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques MOREL, MD, PhD</last_name>
      <phone>+33 467 337 791</phone>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2 infection</keyword>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Spondyloarthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

